FDA tentatively approves Mylan’s generic Eliquis

The FDA has tentatively approved Mylan N.V.’s (MYL -3.3%) generic version of Bristol-Myers Squibb’s (BMY -0.1%) blood thinner Eliquis (apixaban).

Tentative approval means that MYL’s marketing application met the requirements for approval, but patent issues need to be resolved before full approval is granted.

https://seekingalpha.com/news/3476876-fda-tentatively-approves-mylans-generic-eliquis